Cytotoxic T Lymphocyte Antigen 4 Haploinsufficiency Presenting As Refractory Celiac-Like Disease: Case Report.

CTLA4 deficiency CTLA4 haploinsufficiency abatacept autoimmunity case report celiac disease primary immunodeficencies (PID) refractory celiac disease

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 12 03 2022
accepted: 21 06 2022
entrez: 8 8 2022
pubmed: 9 8 2022
medline: 10 8 2022
Statut: epublish

Résumé

Primary immunodeficiency may present with treatment-refractory enteropathy. We present two patients with celiac/celiac-like disease diagnosed in early childhood and refractory to the gluten-free diet. One patient had features of multi-system autoimmunity, whereas the other had celiac-like disease as an isolated clinical finding. Both patients underwent genetic testing given disease refractoriness and were ultimately diagnosed with cytotoxic T lymphocyte antigen 4 (CTLA4) haploinsufficiency. They are both now in complete clinical and endoscopic remission on abatacept. CTLA4 haploinsufficiency has incomplete penetrance and significant phenotypic heterogeneity but should be considered in the differential diagnosis of refractory celiac/celiac-like disease, as treatment implications are significant.

Identifiants

pubmed: 35935971
doi: 10.3389/fimmu.2022.894648
pmc: PMC9352891
doi:

Substances chimiques

CTLA-4 Antigen 0

Types de publication

Case Reports Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

894648

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007477
Pays : United States
Organisme : NIDDK NIH HHS
ID : RC2 DK122532
Pays : United States

Informations de copyright

Copyright © 2022 Collen, Salgado, Bao, Janssen, Weir, Goldsmith, Leichtner, Sabery Khavari, Gernez and Snapper.

Déclaration de conflit d'intérêts

SS declares the following interests: scientific advisory board participation for Pfizer, BMS, Lilly, IFM Therapeutics, Merck, and Pandion Inc; grant support from Pfizer, Novartis, and Takeda; consulting for Hoffman La Roche, Takeda, and Amgen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Rev Immunol. 2011 Nov 25;11(12):852-63
pubmed: 22116087
J Allergy Clin Immunol. 2022 Feb;149(2):736-746
pubmed: 34111452
Immunol Rev. 2019 Jan;287(1):33-49
pubmed: 30565239
J Clin Immunol. 2016 Jan;36(1):8-11
pubmed: 26686526
Blood. 2017 Mar 16;129(11):1458-1468
pubmed: 28159733
Clin Exp Immunol. 2017 Jun;188(3):363-370
pubmed: 27753065
Front Immunol. 2018 Sep 10;9:2012
pubmed: 30250467
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
J Allergy Clin Immunol. 2018 Dec;142(6):1932-1946
pubmed: 29729943
Nat Med. 2014 Dec;20(12):1410-1416
pubmed: 25329329
Front Immunol. 2021 Feb 26;12:619246
pubmed: 33717114
Am J Gastroenterol. 2010 Oct;105(10):2262-75
pubmed: 20551941
J Allergy Clin Immunol. 2018 Mar;141(3):1050-1059.e10
pubmed: 28601686

Auteurs

Lauren V Collen (LV)

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Carlos Andres Salgado (CA)

Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.

Bin Bao (B)

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Erin Janssen (E)

Division of Immunology, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Dascha Weir (D)

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Jeffrey Goldsmith (J)

Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Alan Leichtner (A)

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Nasim Sabery Khavari (N)

Division of Pediatric Gastroenterology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.

Yael Gernez (Y)

Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.

Scott B Snapper (SB)

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH